Prediction of 2-[18F]FDG PET-CT SUVmax for Adrenal Mass Characterization: A CT Radiomics Feasibility Study
- PMID: 37444549
- PMCID: PMC10340369
- DOI: 10.3390/cancers15133439
Prediction of 2-[18F]FDG PET-CT SUVmax for Adrenal Mass Characterization: A CT Radiomics Feasibility Study
Abstract
Background: Indeterminate adrenal masses (AM) pose a diagnostic challenge, and 2-[18F]FDG PET-CT serves as a problem-solving tool. Aim of this study was to investigate whether CT radiomics features could be used to predict the 2-[18F]FDG SUVmax of AM.
Methods: Patients with AM on 2-[18F]FDG PET-CT scan were grouped based on iodine contrast injection as CT contrast-enhanced (CE) or CT unenhanced (NCE). Two-dimensional segmentations of AM were manually obtained by multiple operators on CT images. Image resampling and discretization (bin number = 16) were performed. 919 features were calculated using PyRadiomics. After scaling, unstable, redundant, and low variance features were discarded. Using linear regression and the Uniform Manifold Approximation and Projection technique, a CT radiomics synthetic value (RadSV) was obtained. The correlation between CT RadSV and 2-[18F]FDG SUVmax was assessed with Pearson test.
Results: A total of 725 patients underwent PET-CT from April 2020 to April 2021. In 150 (21%) patients, a total of 179 AM (29 bilateral) were detected. Group CE consisted of 84 patients with 108 AM (size = 18.1 ± 4.9 mm) and Group NCE of 66 patients with 71 AM (size = 18.5 ± 3.8 mm). In both groups, 39 features were selected. No statisticallyf significant correlation between CT RadSV and 2-[18F]FDG SUVmax was found (Group CE, r = 0.18 and p = 0.058; Group NCE, r = 0.13 and p = 0.27).
Conclusions: It might not be feasible to predict 2-[18F]FDG SUVmax of AM using CT RadSV. Its role as a problem-solving tool for indeterminate AM remains fundamental.
Keywords: PET-CT; SUVmax; adrenal glands; neoplasms; radiomics.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
[18F]FDG-PET/CT radiomics for the identification of genetic clusters in pheochromocytomas and paragangliomas.Eur Radiol. 2022 Oct;32(10):7227-7236. doi: 10.1007/s00330-022-09034-5. Epub 2022 Aug 24. Eur Radiol. 2022. PMID: 36001126 Free PMC article.
-
CT radiomics analysis of lung cancers: Differentiation of squamous cell carcinoma from adenocarcinoma, a correlative study with FDG uptake.Eur J Radiol. 2020 Jul;128:109032. doi: 10.1016/j.ejrad.2020.109032. Epub 2020 Apr 26. Eur J Radiol. 2020. PMID: 32361604
-
Diagnostic efficacy of 18F-FDG PET/CT in patients with adrenal incidentaloma.Endocr Connect. 2019 Jul;8(7):838-845. doi: 10.1530/EC-19-0204. Endocr Connect. 2019. PMID: 31137014 Free PMC article.
-
A review on advances in 18F-FDG PET/CT radiomics standardisation and application in lung disease management.Insights Imaging. 2022 Feb 5;13(1):22. doi: 10.1186/s13244-021-01153-9. Insights Imaging. 2022. PMID: 35124733 Free PMC article. Review.
Cited by
-
Artificial intelligence-based application in multiple myeloma.Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):1923-1925. doi: 10.1007/s00259-024-06711-z. Eur J Nucl Med Mol Imaging. 2024. PMID: 38587646 No abstract available.
-
[18F]FET PET/MR and machine learning in the evaluation of glioma.Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):797-799. doi: 10.1007/s00259-023-06505-9. Eur J Nucl Med Mol Imaging. 2024. PMID: 37953393 No abstract available.
References
LinkOut - more resources
Full Text Sources
Miscellaneous